The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On June 4, IMUNON entered into definitive agreements for $10 million in financing to support ovarian cancer clinical trials. The financing includes $2.5 million in preferred stock issuance and $7.72 million in secured promissory notes. Proceeds will fund the Phase 3 OVATION 3 study of IMNN-001 in advanced ovarian cancer.